Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02378883 · ClinicalTrials.gov registry record · NA
Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study
A NA study, sponsored by Medtronic Neurovascular Clinical Affairs.
- Completed
- Registry status
- NA
- Development phase
- 112
- Enrollment target
NCT02378883: Completed NA study, sponsored by Medtronic Neurovascular Clinical Affairs.
NCT02378883 is a NA study that has completed, run by Medtronic Neurovascular Clinical Affairs. The registered enrollment target is 112 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02378883, a NA study, has completed, sponsored by Medtronic Neurovascular Clinical Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of the Apollo™ Onyx™ Delivery Microcatheter used for delivery of the Onyx™ Liquid Embolic System during brain arteriovenous malformation (AVM) embolization procedures.
Primary Outcome
Premature (unintentional) catheter tip detachment with clinical sequelae Catheter rupture/break/fracture with clinical sequelae Retained catheter body in the vasculature
Interventions
- DEVICE Apollo™ Onyx™ Delivery Micro Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2015-05-18 |
| Est. Completion | 2018-02-20 |
| Phase | NA |
What the finished NCT02378883 record still lists
NCT02378883 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Apollo™ Onyx™ Delivery Micro Catheter is the first listed.
NCT02378883 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02378883 about?
NCT02378883 is a clinical study titled "Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study". The purpose of this study is to evaluate the safety of the Apollo™ Onyx™ Delivery Microcatheter used for delivery of the Onyx™ Liquid Embolic System during brain arteriovenous malformation (AVM) embolization procedures.
What is the current status of trial NCT02378883?
This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2015-05-18. Estimated completion is 2018-02-20.
What interventions are being tested in trial NCT02378883?
The interventions under investigation include: Apollo™ Onyx™ Delivery Micro Catheter (DEVICE).
Who is sponsoring clinical trial NCT02378883?
This trial is sponsored by Medtronic Neurovascular Clinical Affairs, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02378883's enrollment target sits among peer trials
112 813th of 2000 higher than 1,185 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI